Last reviewed · How we verify
NCT04405375
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Phase 2 trial testing gemcitabin in Extranodal NK/T-cell Lymphoma, Nasal Type in 29 participants. Status unknown.
30 April 2023
Quick facts
| Lead sponsor | Beijing Tongren Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 21 March 2020 |
| Primary completion | 30 April 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- gemcitabin — full drug profile →
- Pegaspargase — full drug profile →
- Etoposide (etoposide) — full drug profile →
- Dexamethasone (dexamethasone) — full drug profile →
Conditions studied
- Extranodal NK/T-cell Lymphoma, Nasal Type — all drugs for Extranodal NK/T-cell Lymphoma, Nasal Type →
Sponsor
Beijing Tongren Hospital
Who can join
Adults 18 to 75, any sex, with Extranodal NK/T-cell Lymphoma, Nasal Type. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The contemporary management of cancers of the sinonasal tract in adults.
Thawani R, Kim MS, Arastu A, Feng Z, et al · · 2023 · cited 95× · PMID 35916666 · DOI 10.3322/caac.21752
Verify or expand the search:
- PubMed search for NCT04405375
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Extranodal NK/T-cell Lymphoma, Nasal Type
Currently open trials in the same condition.
- NCT05978141 — A Registry for People With T-cell Lymphoma · recruiting
- NCT04414163 — A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type · Phase 2 · active not recruiting
Other Beijing Tongren Hospital trials
Trials by the same sponsor.
- NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
- NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04405375 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
- Last refreshed: 28 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04405375.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing